Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously presented) A compound of formula (I)



(I)

A represents thiophene;

R^1 represents a phenyl group; said phenyl being optionally substituted by one or more substituents selected independently from halogen, cyano, nitro, $-NR^3R^4$, $-CONR^5R^6$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-S(O)_mR^{10}$, $-S(O)_2NR^5R^6$, $-NR^8SO_2R^{10}$, C_1-C_6 alkyl, trifluoromethyl, $-(CH_2)_nR^{11}$, $-O(CH_2)_nR^{11}$ or $-OR^{12}$;

R^2 represents hydrogen, halogen, cyano, nitro, $-NR^{13}R^{14}$, $-CONR^{15}R^{16}$, $-COOR^{17}$, $-NR^{18}COR^{19}$, $-S(O)_mR^{20}$, $-S(O)_2NR^{15}R^{16}$, $-NR^{18}SO_2R^{20}$, C_1-C_2 alkyl, trifluoromethyl, C_2-C_3 alkenyl, C_2-C_3 alkynyl, trifluoromethoxy, C_1-C_2 alkoxy or C_1-C_2 alkanoyl;

X represents oxygen or sulfur;

each of R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10} and R^{12} independently represent a hydrogen atom or C_1-C_6 alkyl;

R^{11} represents $NR^{21}R^{22}$ where R^{21} and R^{22} are independently hydrogen or C_1-C_6 alkyl optionally substituted by C_1-C_4 alkoxy; or R^{21} and R^{22} together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR^{23} group where R^{23} is hydrogen or C_1-C_6 alkyl; or R^{11} represents OR^{24} where R^{24} represents C_1-C_6 alkyl;

each of R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19} and R^{20} independently represent a hydrogen atom or C_1-C_2 alkyl;

m represents an integer 0, 1 or 2;

n represents an integer 2, 3 or 4;

and optical isomers, racemates, and tautomers thereof and pharmaceutically acceptable salts or solvates thereof:

provided that:

when A represents thiophene, then R^1 is not 4-pyridinyl or 3-pyrazolyl.

2. (Previously presented) A compound of formula (I), according to Claim 1, wherein X represents oxygen.

3. (Previously presented) A compound of formula (I), according to Claim 1, in which the group A is substituted as shown below in formula (Ia), where B and D are selected from CR^2 and S, where R^2 is as defined in Claim 1 and R^{25} is hydrogen or C_1-C_6 alkyl:



(Ia)

4-5. (Cancelled)

6. (Previously presented) A compound according to claim 1 in which R^2 represents H or methyl.

7. (Original) A compound according to Claim 6 in which R^2 represents H.

8. (Presently amended) A compound of formula (I), according to claim 1, selected from:
3-[(aminocarbonyl)amino]-5-phenyl-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(3-chlorophenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(4-isobutylphenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(2-chlorophenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{2-[2-(dimethylamino)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{4-[2-(dimethylamino)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-2-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-phenyl-3-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{4-[2-(1-morpholinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{4-[2-(1-pyrrolidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{4-[2-(1-piperidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{4-[3-(dimethylamino)propoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{3-[2-(dimethylamino)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{3-[2-(1-morpholinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{3-[2-(1-pyrrolidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{3-[2-(1-piperidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{3-[3-(dimethylamino)propoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{2-[2-(1-morpholinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{2-[2-(1-pyrrolidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{2-[2-(1-piperidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;

3-[(aminocarbonyl)amino]-5-{2-[3-(dimethylamino)propoxy]phenyl}-2-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-chlorophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-methylphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-ethyl-5-phenyl-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-methoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-fluorophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3-fluorophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3-methoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3-chloro-4-methoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(2-chlorophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3-trifluoromethylphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3-methyl-4-methoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3,5-dimethoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(2,3-dimethoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-isopropylphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3,4,5-trimethoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(3,4-dichlorophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-cyanophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-hydroxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-[2-(1-piperidinyl)ethoxy]phenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(4-[2-(diethylamino)ethoxy]phenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-trifluoromethyl-5-phenyl-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-phenyl-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-trifluoromethylphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(2,4-difluorophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-methanesulphonylphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-[2-(1-piperidinyl)ethoxy]phenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-[2-(1-(2,2,6,6-tetramethyl)piperidinyl)ethoxy]phenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-(thiazol-4-yl-methoxy)phenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-[2-(dimethylamino)ethoxy]phenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-[2-(diethylamino)ethoxy]phenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-[2-(1-morpholinyl)ethoxy]phenyl)-3-thiophenecarboxamide;

2-[(aminothiocarbonyl)amino-5-phenyl-3-thiophenecarboxamide;

and pharmaceutically acceptable salts and solvates thereof.

9. (Previously presented) A process for the preparation of a compound of formula (I), according to claim 1, which comprises:

(a) reaction of a compound of formula (II):



(II)

wherein A, R^1 and R^2 are as defined in Claim 1 with an isocyanate (X = O) or an isothiocyanate (X = S); or

(b) reaction of compound of formula (III) with a compound of formula (IV)

R^1-Metal



(III) (IV)

wherein A, X, R^1 and R^2 are as defined in Claim 1 and LG represents a leaving group; or

(c) reaction of compound of formula (V) with a compound of formula (VI)

R^1-LG



(V) (VI)

wherein A, X, R^1 and R^2 are as defined in Claim 1 and LG represents a leaving group;

and where necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of formula (I) into a further compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

10. (Previously presented) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

11. (Previously presented) A process for the preparation of a pharmaceutical composition which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

12-19. (Cancelled)

20. (Previously presented) A method of treating an IKK2 mediated disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claims 1.

21. (Previously presented) A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

22. (Original) A method according to claim 21, wherein the disease is asthma.

23. (Original) A method according to claim 21, wherein the disease is rheumatoid arthritis.

24. (Original) A method according to claim 21, wherein the disease is multiple sclerosis.

25. (Original) A method according to claim 21, wherein the disease is chronic obstructive pulmonary disease.

26. (Previously presented) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 8, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.